Decision Framework for Antihypertensive Therapy in Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Antihypertensive therapy selection in veterinary patients necessitates a structured framework prioritizing accurate blood pressure measurement, identification of target-organ damage (eyes, kidneys, heart, brain), and determination of the underlying cause (renal, endocrine, idiopathic, drug-induced).
• Species-specific differences are critical: amlodipine is the first-line agent for feline hypertension due to its efficacy and tolerability, while ACE inhibitors are preferred for dogs with proteinuric chronic kidney disease due to their antiproteinuric effects.
• Treatment escalation follows a defined sequence, typically adding a second drug class (e.g., ACE inhibitor to amlodipine in cats, or amlodipine to ACE inhibitor in dogs) rather than solely increasing the dose of the initial agent, with spironolactone considered for resistant hypertension in dogs.
• Rigorous monitoring is paramount, including serial systolic blood pressure measurements to assess efficacy, serum creatinine and SDMA to detect worsening renal function, urine protein-to-creatinine ratio for glomerular injury, and fundic examination for retinal damage.
• Common errors include initiating therapy based on a single elevated reading, selecting agents based solely on blood pressure magnitude rather than underlying cause, and failing to reassess blood pressure after dose adjustments, all of which can lead to undertreatment or overtreatment.
• The ACVIM consensus statement serves as the primary reference, emphasizing that while evidence from prospective trials is limited, current guidelines are based on expert opinion and extrapolation from human medicine, necessitating careful clinical judgment and patient-specific adjustments.

Systemic hypertension in dogs and cats is a common clinical problem that demands a structured approach to therapy selection. This article provides a decision framework for choosing antihypertensive medication based on the underlying cause, the species affected, and the presence of target-organ damage. It is written for veterinary students who already understand blood pressure physiology and the pharmacology of common antihypertensive drug classes but need a reproducible method for translating that knowledge into patient-specific plans.

The framework presented here follows the diagnostic-reasoning pathway recommended in the ACVIM consensus statement on identification, evaluation, and management of systemic hypertension in dogs and cats. That document remains the primary reference for clinical decision-making in veterinary hypertension. The framework also draws on principles from human hypertension management, particularly the recognition that treatment selection depends on accurate measurement, assessment of target-organ damage, and identification of secondary causes, as outlined in the institutional review of hypertension pathophysiology and therapy.

The reader should note that this article deliberately excludes specific drug doses. Current formulary and label references must be consulted before prescribing. The goal here is to establish the reasoning structure that determines which drug class, which combination, and which monitoring schedule fit a given patient.

At a Glance

Physiology of Blood Pressure Regulation Relevant to Drug Selection

Blood pressure is the product of cardiac output and systemic vascular resistance. The kidney, the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and vascular endothelium all contribute to its regulation. In dogs and cats, as in humans, hypertension arises when these systems fail to maintain normal pressure, often because of an identifiable underlying disease.

The RAAS is the dominant pharmacological target in veterinary antihypertensive therapy. Angiotensin II is a potent vasoconstrictor and stimulates aldosterone release, which promotes sodium and water retention. Interrupting this cascade with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) reduces vascular resistance and blood volume. The human hypertension literature identifies ACE inhibitors, ARBs, dihydropyridine calcium-channel blockers, and thiazide diuretics as first-line agents, and this hierarchy has influenced veterinary practice, though species differences modify the order of preference.

The sympathetic nervous system contributes to acute pressure regulation and to chronic hypertension in some disease states. Beta-blockers and centrally acting agents target this arm but are rarely first-line in veterinary patients. Calcium-channel blockers, specifically the dihydropyridine class, reduce vascular resistance by blocking calcium entry into vascular smooth muscle. They act independently of the RAAS, which makes them particularly useful when RAAS blockade alone is insufficient.

Species Differences in Hypertension Pathophysiology

Dogs and cats differ in the typical causes of hypertension, and this difference drives drug selection. In dogs, hypertension is most often secondary to chronic kidney disease, hyperadrenocorticism, diabetes mellitus, or pheochromocytoma. In cats, chronic kidney disease and hyperthyroidism dominate, with a substantial proportion of cases classified as idiopathic.

These differences matter clinically. A dog with proteinuric chronic kidney disease and hypertension will benefit from an ACE inhibitor, which reduces both blood pressure and proteinuria. A cat with hyperthyroidism and hypertension may improve with thyroid hormone normalization alone, and antihypertensive therapy may be deferred or adjusted after the thyroid status is controlled. The ACVIM consensus statement emphasizes that identification and treatment of the underlying disease is an essential component of hypertension management in both species.

Feline hypertension also carries a distinctive risk profile. The cat eye is highly susceptible to hypertensive damage, and retinal detachment or intraocular hemorrhage can occur at pressures that would be tolerated in a dog. This makes the ophthalmologic examination a critical determinant of treatment urgency in cats. The same consensus statement identifies target-organ damage as a key factor in deciding how aggressively to treat.

The Diagnostic Sequence Before Therapy

Therapy selection begins with diagnosis, not with a drug. The sequence recommended by the ACVIM consensus statement is to confirm hypertension with accurate measurement, identify target-organ damage, search for an underlying cause, and then select therapy. Skipping any of these steps risks treating the wrong patient or choosing the wrong drug.

Accurate measurement requires a Doppler or oscillometric device, an appropriately sized cuff, and a quiet environment. Multiple readings are needed because stress-induced elevations are common, particularly in cats. The consensus statement provides species-specific thresholds that define hypertension and guide treatment decisions. These thresholds are not arbitrary, they reflect the pressures at which target-organ damage becomes likely.

The search for an underlying cause includes a minimum database of biochemistry, urinalysis, and thyroid hormone measurement in cats. Additional testing, such as adrenal function testing in dogs or abdominal imaging, is guided by signalment and physical examination findings. The goal is to distinguish secondary hypertension, where treatment of the primary disease may reduce or eliminate the need for antihypertensive drugs, from primary or idiopathic hypertension, where lifelong therapy is expected.

Pharmacological Classes and Their Position in the Framework

The major drug classes used in veterinary antihypertensive therapy are ACE inhibitors, ARBs, dihydropyridine calcium-channel blockers, and beta-blockers. Each occupies a defined position in the decision framework.

ACE inhibitors are the first-line choice in dogs with proteinuric chronic kidney disease. They reduce glomerular capillary pressure and proteinuria in addition to lowering systemic pressure. ARBs block the angiotensin II receptor directly and may be used when ACE inhibitor intolerance occurs, though clinical experience in dogs is more limited than in cats. The human hypertension review confirms that both classes are effective first-line agents, and veterinary guidelines have adopted a similar position.

Dihydropyridine calcium-channel blockers, particularly amlodipine, are the first-line choice in cats. They are potent vasodilators, well tolerated, and effective even when the RAAS is not the dominant driver of hypertension. In dogs, amlodipine is used as an add-on agent when ACE inhibition alone is insufficient. The ACVIM consensus statement supports this species-specific ordering.

Beta-blockers have a narrow role in veterinary hypertension. They are indicated when a specific condition, such as hyperthyroidism in cats, produces tachycardia and hypertension, or when concurrent cardiac disease requires rate control. They are not first-line for uncomplicated hypertension in either species.

The Decision Framework

The framework proceeds through five sequential questions. First, is the blood pressure above the treatment threshold defined by the ACVIM consensus statement? Second, is there target-organ damage that mandates immediate therapy? Third, what is the underlying cause, and can it be treated directly? Fourth, are there comorbidities that favour or contraindicate specific drug classes? Fifth, what monitoring schedule will be used to assess response?

In dogs, the default first agent is an ACE inhibitor when proteinuria or chronic kidney disease is present. If the pressure target is not reached, a dihydropyridine calcium-channel blocker is added. In cats, the default first agent is amlodipine, with an ACE inhibitor added if proteinuria persists or if pressure control is incomplete. This ordering reflects the evidence base summarized in the ACVIM consensus statement and the practical experience of veterinary clinicians.

Resistant hypertension, defined as failure to reach target on two or three appropriately dosed drugs, triggers a re-evaluation of the diagnosis, the measurement technique, client compliance, and the possibility of an undiagnosed secondary cause. It does not simply prompt the addition of a fourth drug.

Monitoring Parameters and Their Clinical Meaning

The decision to start antihypertensive therapy is only the first step. Every subsequent decision, whether to escalate, add, switch, or withdraw a drug, depends on a structured monitoring protocol. The ACVIM consensus statement on systemic hypertension in dogs and cats defines the target ranges and the measurement standards that should govern therapy adjustment.

Blood pressure measurement must be standardized at every visit. Use the same cuff size, the same limb, and the same method, ideally in a quiet room with the patient allowed to acclimate for five to ten minutes. Five to seven valid readings should be taken, discarding the first and averaging the remainder. The measurement method, whether Doppler or oscillometric, should be recorded because the two techniques do not produce identical values and the difference matters when comparing serial readings.

The interval between rechecks depends on the severity of hypertension at presentation and the agent chosen. A patient with systolic pressure above 180 mmHg and evidence of target-organ damage should be rechecked within 3 to 7 days of starting therapy. A patient with mild hypertension and no detectable target-organ damage can be rechecked at 10 to 14 days. Once the target is reached, recheck at 1 month, then every 3 to 6 months depending on the stability of the underlying disease.

The Decision Tree for Initial Agent Selection

The framework below integrates the diagnostic sequence with drug class selection. The ACVIM consensus statement provides the evidence base for the first-line positions assigned to each class.

Step 1: Confirm persistent hypertension. A single elevated reading does not justify therapy. Confirm with a second visit unless systolic pressure exceeds 180 mmHg with concurrent target-organ damage, in which case treatment should begin without delay.

Step 2: Identify the underlying cause. The diagnostic sequence from Part 1 determines whether the hypertension is renal, endocrine, or idiopathic. This classification drives the initial drug choice.

Step 3: Select the first-line agent by species and cause.

• Feline hypertension, any cause: amlodipine is the first-line agent. Its predictable efficacy and once-daily dosing make it the default choice. If the cat is azotaemic, amlodipine remains appropriate because it does not depend on renal perfusion for its effect.
• Canine hypertension with proteinuric kidney disease: an ACE inhibitor is the first-line agent. The antiproteinuric effect is the therapeutic goal in addition to pressure reduction.
• Canine hypertension without proteinuria: amlodipine is the first-line agent. ACE inhibitors are reserved for patients who do not achieve target with amlodipine alone or who develop proteinuria during follow-up.
• Canine hypertension with hyperadrenocorticism: treat the underlying endocrinopathy first. If hypertension persists after adequate control of cortisol excess, add amlodipine.

Step 4: Escalate according to a defined sequence. If the first-line agent fails to achieve target within the expected time frame, do not simply increase the dose indefinitely. Add a second agent from a different class. In dogs, the typical sequence is ACE inhibitor plus amlodipine. In cats, amlodipine plus an ACE inhibitor is used when amlodipine alone is insufficient, although the evidence for added benefit is limited.

Step 5: Consider spironolactone in dogs with resistant hypertension. This is a third-line option, particularly when hyperaldosteronism is suspected or when heart failure is concurrent. Its use requires monitoring of potassium and renal function.

Species-Specific Decision Points

The choice of agent differs between dogs and cats for reasons that are partly pharmacological and partly based on the typical underlying disease. Feline hypertension is most often idiopathic or associated with chronic kidney disease, and amlodipine reliably lowers pressure in the majority of affected cats. Canine hypertension is more frequently secondary to renal disease or endocrinopathy, and the treatment target must account for the need to preserve renal function while reducing pressure.

The MSD Veterinary Manual provides species-specific guidance on drug selection and monitoring that complements the consensus statement. The practical consequence is that a dog with proteinuric kidney disease and a cat with the same condition will not receive the same first-line drug, even though the underlying diagnosis is similar.

Age modifies the decision. Older cats are more likely to have chronic kidney disease and are also more susceptible to the hypotensive effects of amlodipine at the upper end of the dose range. Older dogs with degenerative mitral valve disease may require an ACE inhibitor for cardiac reasons, which then becomes the antihypertensive agent of choice even if proteinuria is absent.

Monitoring Parameters and What Each One Detects

The monitoring protocol must detect three categories of change: inadequate pressure control, drug adverse effects, and progression of the underlying disease. Each parameter in the table above serves one of these categories.

Systolic blood pressure is the primary efficacy parameter. It detects inadequate control and guides dose adjustment. It does not detect adverse effects or disease progression, which is why the other parameters are required.

Serum creatinine and SDMA detect declining renal function. A rising trend may indicate that the pressure has been lowered too aggressively, reducing renal perfusion, or that the underlying kidney disease is progressing independently. The distinction matters because the response differs: the former requires dose reduction, the latter requires continued or intensified therapy.

The urine protein:creatinine ratio detects glomerular injury. In dogs, an ACE inhibitor is indicated when proteinuria is present, regardless of the blood pressure value. In cats, proteinuria is less consistently linked to hypertension, and the decision to use an ACE inhibitor is made on an individual basis.

Optic funduscopy detects retinal target-organ damage. It is the most direct measure of whether hypertension is causing end-organ injury, and it should be performed at diagnosis and at each recheck until the pressure is controlled. New retinal lesions in a patient with controlled pressure warrant investigation for an underlying cause that has been missed.

Serum potassium detects the hyperkalemic effect of ACE inhibitors and spironolactone. It should be measured 7 to 10 days after starting or increasing the dose of either drug, then at each recheck.

Documentation and Communication of the Treatment Plan

The medical record must document the blood pressure values obtained at each visit, the method used, the cuff size, the limb used, and the number of readings averaged. This allows the next clinician to reproduce the measurement conditions and to interpret serial trends accurately.

The treatment plan should be recorded as a structured decision: the underlying cause, the target pressure, the initial agent and its rationale, the recheck interval, and the escalation sequence if the target is not met. The owner should receive a written summary that includes the target pressure, the drug name and administration schedule, and the signs that warrant an earlier recheck, such as acute blindness, seizures, or lethargy.

Printed educational materials have a measurable effect on professional practice when they are used as part of a structured implementation strategy, as described in the Cochrane review of printed educational materials. The same principle applies to owner communication: a written plan is more likely to be followed than a verbal instruction, particularly for a chronic condition that requires long-term therapy.

The framework presented here is a guide, not a protocol. Individual patients will deviate from the expected response, and the clinician must be prepared to adjust the plan based on the monitoring parameters above. The ACVIM consensus statement remains the reference standard for the identification, evaluation, and management of systemic hypertension in dogs and cats, and it should be consulted when the clinical picture is ambiguous.

Recognized Complications and Early Detection

The principal complications of antihypertensive therapy in dogs and cats are hypotension, worsening azotaemia, and failure of target-organ protection despite adequate blood pressure control. Hypotension is the most immediate risk, particularly in animals with concurrent systemic disease or those receiving multiple agents. The ACVIM consensus statement on hypertension management recommends that blood pressure be reassessed within 7 to 14 days of initiating or changing therapy, with earlier reassessment in animals with baseline azotaemia, hypoalbuminaemia, or suspected volume depletion. Clinical signs of hypotension, including weakness, lethargy, syncope, and acute deterioration in renal function, warrant immediate measurement of blood pressure and reduction or temporary cessation of therapy.

Worsening azotaemia is a recognized complication of renin-angiotensin-aldosterone system blockade, particularly when combined with diuretics or in animals with pre-existing chronic kidney disease. Early detection relies on serial measurement of serum creatinine and symmetric dimethylarginine (SDMA) at each recheck visit, with particular attention to the first 2 to 4 weeks of therapy. A rise in creatinine of more than 30% from baseline, or an absolute increase that is progressive across two consecutive measurements, should prompt evaluation of volume status, dietary protein intake, and concurrent drug administration before assuming treatment failure.

Failure of target-organ protection can occur even when measured blood pressure appears controlled. This is most commonly recognized in cats with hypertensive retinopathy, where persistent retinal lesions, retinal detachment, or new hemorrhage indicate inadequate end-organ protection. In dogs, progressive proteinuria, echocardiographic evidence of increasing left ventricular wall thickness, or new neurologic signs may signal ongoing hypertensive injury. The MSD Veterinary Manual notes that blood pressure measurements obtained in a stressed or struggling animal may be falsely elevated, leading to overtreatment or undertreatment depending on the clinical context.

Common Errors and Corrective Actions

Less experienced clinicians frequently misinterpret a single elevated blood pressure reading as confirmed hypertension. The ACVIM consensus statement emphasizes that a diagnosis of hypertension requires multiple consistent measurements, ideally across more than one visit, using a standardized protocol with an appropriately sized cuff. The corrective action is to repeat measurements after a 5 to 10 minute acclimatisation period in a quiet room, and to record the average of at least five readings after discarding the first.

A second common error is selecting an agent based on the magnitude of blood pressure elevation instead of the underlying cause. For example, an animal with proteinuric chronic kidney disease and hypertension should receive an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker as first-line therapy, whereas an animal with hyperadrenocorticism and hypertension may respond better to amlodipine while the endocrine disease is being addressed. The human hypertension literature similarly emphasizes that first-line antihypertensive selection should be guided by the presence of comorbidities and underlying pathophysiology instead of the degree of blood pressure elevation alone.

A third error is failure to reassess blood pressure after dose adjustment. Some clinicians prescribe an agent and do not recheck blood pressure for several months, missing both inadequate control and overtreatment. The corrective action is to establish a recheck schedule at the time of prescribing, with blood pressure measurement and laboratory monitoring at each visit until stable control is achieved.

Limitations of the Evidence and Divergent Expert Opinion

The veterinary evidence base for antihypertensive therapy is limited by a relative scarcity of prospective, randomised, controlled trials comparing drug classes in dogs and cats. Much of the current guidance, including the ACVIM consensus statement, is based on expert opinion, extrapolation from human medicine, and retrospective or observational studies. The human hypertension literature demonstrates that treatment reduces cardiovascular morbidity and mortality, but the magnitude of benefit in veterinary patients, and the optimal blood pressure target for each species and comorbidity, remains less precisely defined.

Expert opinion differs on several points. The target blood pressure for dogs with proteinuric kidney disease is generally agreed to be lower than for uncomplicated hypertension, but the exact threshold is debated. Some specialists advocate combining an ACE inhibitor with amlodipine early in therapy, while others prefer sequential addition of agents to identify the effective drug and minimize adverse effects. The role of beta-blockers in feline hypertension is contested, with some experts reserving them for animals with concurrent hypertrophic cardiomyopathy and others avoiding them due to concerns about negative inotropy and masking of hypoglycemia.

Referral, Specialist Consultation, and Laboratory Involvement

Referral to a veterinary cardiologist or internal medicine specialist is warranted when hypertension is refractory to two or more agents at appropriate doses, when target-organ damage progresses despite apparent blood pressure control, or when a secondary cause such as pheochromocytoma, primary hyperaldosteronism, or renal artery stenosis is suspected. Specialist consultation is also appropriate for animals with complex comorbidities, such as concurrent heart failure and kidney disease, where drug selection requires careful balancing of competing risks.

Laboratory involvement is essential in the initial evaluation and ongoing monitoring of hypertensive patients. A minimum database should include serum biochemistry, urinalysis with culture, and urine protein-to-creatinine ratio. Additional testing, including thyroid hormone measurement in cats, adrenal function testing in dogs, and abdominal ultrasonography, may be indicated based on the clinical presentation. The Davis-Thompson Foundation pathology resources provide case material that can assist in interpreting histopathologic findings when target-organ damage is confirmed post-mortem.

Regulatory reporting is rarely required for antihypertensive therapy in companion animals, but clinicians should be aware of local requirements regarding controlled substances, adverse drug reaction reporting, and professional standards. The AVMA practice resources provide guidance on professional obligations and reporting expectations in the United States, while the WOAH terrestrial animal health standards address international expectations for veterinary practice and drug use.

Frequently Asked Questions

How do I select an antihypertensive when the owner has severe cost constraints?

Prioritize the drug class most likely to achieve target blood pressure with the fewest monitoring visits. Amlodipine is generally the first-line agent in cats and often in dogs with proteinuric kidney disease, and its once-daily dosing reduces visit frequency. If amlodipine is unaffordable, discuss with the owner whether twice-daily monitoring of a cheaper agent is feasible, because underdosing wastes money and leaves target organs exposed. The ACVIM consensus statement on hypertension management emphasizes that treatment success depends on sustained therapy, not initial drug cost. Consider whether the owner can commit to recheck appointments before prescribing, and document the financial discussion in the record.

What should I do when an accurate Doppler or oscillometric device is unavailable?

Do not initiate or adjust therapy based on a single unreliable reading. If no validated device exists in the practice, refer the patient for blood pressure measurement or postpone non-urgent treatment decisions until measurement is possible. For patients with suspected hypertensive target-organ damage, such as acute blindness or retinal detachment, treatment cannot wait, use the lowest starting dose of a first-line agent and recheck as soon as measurement becomes available. The ACVIM guidelines for identification and management of systemic hypertension stress that accurate measurement is the foundation of diagnosis. Record the method used, the cuff size, and the number of readings in the medical record.

How does the decision framework change for a dog versus a cat with the same underlying disease?

The framework diverges mainly in first-line agent choice and monitoring frequency. In cats, amlodipine is the preferred initial agent regardless of underlying cause, because amlodipine is effective and well tolerated in this species. In dogs, the underlying disease matters more: proteinuric chronic kidney disease favours an ACE inhibitor or angiotensin receptor blocker, whereas amlodipine is added when target blood pressure is not reached. The ACVIM consensus statement notes that dogs with hyperadrenocorticism or phaeochromocytoma may require different combinations. Cats also need more frequent rechecks early in therapy because their blood pressure can fall rapidly once amlodipine is started.

What monitoring schedule should I recommend when the owner cannot return for frequent rechecks?

Set a realistic minimum: one recheck within 7 to 14 days of starting or changing therapy, then at 1 month, then every 3 to 6 months once stable. If the owner cannot commit to even the first recheck, reconsider whether to start therapy at all, because unmonitored antihypertensive use risks hypotension and kidney injury. The ACVIM consensus statement on systemic hypertension recommends rechecking blood pressure and renal parameters after each dose adjustment. For cats on amlodipine, also reassess kidney values because blood pressure reduction can unmask underlying renal disease. Document the agreed schedule in writing and ask the owner to confirm understanding.

How should I document the treatment plan and response in the medical record?

Record the indication for therapy, the target blood pressure, the drug and formulation chosen, the starting dose, and the planned recheck date. At each recheck, document the blood pressure method, cuff size, number of readings, the average value, and any adverse effects reported. Note whether target blood pressure was achieved and what change was made. The AVMA practice resources emphasize that clear documentation supports continuity of care and defensible decision-making. Also record client communication, including cost discussions and the owner's stated ability to comply. If the owner declines a recommended recheck, document that refusal and the rationale discussed.

How do I explain to an owner why their pet needs lifelong antihypertensive therapy when the pet appears well?

Frame the discussion around silent organ damage instead of visible signs. Explain that high blood pressure damages the kidneys, eyes, heart, and brain even when the pet seems normal, and that medication protects these organs. Use the analogy of a silent disease that requires monitoring, not a condition the owner can judge by appearance. The MSD Veterinary Manual provides client-oriented explanations of hypertension that can support your discussion. Emphasize that stopping medication without veterinary advice can cause rebound effects or allow silent progression. Offer a written summary of the treatment plan and recheck schedule, and invite the owner to call with concerns between visits.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Hypertension.. 2018.
• Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting.. 2011.
• ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.. 2018.
• Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition.. 2019.
• Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension.. 2010.
• Printed educational materials: effects on professional practice and healthcare outcomes.. 2012.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Decision Framework for Anticoagulant Therapy in Veterinary Patients
• Decision Framework for Antiemetic Therapy in Veterinary Patients
• Decision Framework for Choosing Antifungal Therapy in Veterinary Patients
• Decision Framework for Antiviral Therapy in Veterinary Patients
• Decision Framework for Antiparasitic Therapy in Companion Animals

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.